PCSK9 and myocardial infarction: Similar findings were observed in the Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients with Acute Myocardial Infarction (PACMAN-AMI) study, in which addition of alirocumab to a statin produced plaque regression on intravascular ultrasound, reductions in plaque macrophages on optical coherence tomography and lipid cores on near infrared spectroscopy [59].